NEWS
Press release: invIOs to present at Biotech Showcase
Press release: invIOs presents positive patient data from ongoing Phase 1b trial of APN401 cell therapy in advanced solid tumors at SITC 2022
Press release: APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01
Administration of aerosolized APN01 shown to be safe and well tolerated at all dose levels, with no adverse events above Grade 2 Investigators recommend further development of inhaled APN01, which…
Press release: invIOs to present data from clinical stage Cbl-b program at SITC 2022
Vienna, Austria, 18 October 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that two abstracts on its clinical stage lead program, APN401,…
Press release: invIOs to present at upcoming industry and investor conferences
Press release: APEIRON shareholders approve new group structure
Press release: invIOs to present at upcoming conferences
Press release: invIOs goes live
invIOs goes live with unique cell therapy platform and clinical-stage immuno-oncology pipeline Vienna, Austria, 16 December 2021: invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for…
Press release: APEIRON Biologics launches next clinical trial with innovative cancer therapy APN401
Important development step for promising cell therapy Paradigm shift in cancer treatment: process developed by APEIRON uses immune system to treat solid tumors Innovative new manufacturing and treatment process enables…
Press release: APEIRON Biologics announces changes to management and supervisory boards
Management Board to be expanded by Romana Gugenberger, PhD, as Chief Medical & Scientific Officer (CMSO) and Andreas Gerber, PhD, as Chief Operating Officer (COO) Prof. Josef Penninger moves from…
